Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 26 May 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Treating Hep C reinfection after liver transplant

Combination therapy with interferon-2b and ribavirin in transplanted patients with chronic Hepatitis C is effective, well tolerated and improves histological outcome, reports the latest issue of Liver International.

News image

fiogf49gjkf04

Recurrence of Hepatitis C virus infection after orthotopic liver transplantation is a virtually universal occurrence.

A significant proportion of patients develop chronic Hepatitis and cirrhosis.

Dr Süleyman Yedibela and colleagues from Germany evaluated the safety and efficacy of interferon-2b plus ribavirin.

After 3 months, 73% of patients were free from Hepatitis C virus RNA
Liver International

The researchers assessed the efficacy of this combination therapy in the treatment of recurrent Hepatitis C after othotopic liver transplantation over the long term.

The research team started 15 patients with recurrent Hepatitis C infection on interferon-2b plus ribavirin 18 months after orthotopic liver transplantation.

Interferon-2b was given as 36 million units and administered subcutaneously 3 times a week, whilst ribavirin was administered at 800 to 1200 mg/day.

The team defined recurrent Hepatitis C infection where there was positive serum Hepatitis C RNA, elevated serum aminotransferases, and histological activity.

Hepatitis C virus RNA was determined 1, 3, 6, 9, 12 and 18 months after initiation of treatment.

The researchers performed liver biopsy before and after therapy and followed up the patients for a mean of 33 months.

The team found that 87% of patients were treated for at least 6 months and 60% for 12 months.

After 3 months, the team noted that 73% were free from Hepatitis C RNA, with less than 50 copies/ml, and that virological end-of-treatment response was 67%.

The researchers observed that 33% remained Hepatitis C RNA-negative 6 months posttreatment.

During the follow-up period, 27% died of liver failure, recurrent Hepatitis C after virological response, or hepatocellular carcinoma.

The researchers found that histological activity index improved significantly for both inflammatory activity and fibrosis, from 9 to 5 and from 7 to 5, respectively.

In none of the patients signs of rejection were observed.

Dr Yedibela's team concludes, “Combination therapy with interferon and ribavirin in transplanted patients with chronic Hepatitis C is an effective treatment that results in a high virological SR rate.”

“It is well tolerated and leads to an improvement in histological outcome.”

Liver Int 2005: 25(4): 717
07 July 2005

Go to top of page Email this page Email this page to a colleague

 25 May 2018 
Colorectal cancer–specific mortality
 25 May 2018 
Technology to increase colorectal cancer screening
 25 May 2018 
Post‐operative complications in elderly IBD
 24 May 2018 
Patient-reported outcome measures in IBD trials
 24 May 2018 
Alcohol consumption and outcomes in drug-induced liver injury
 24 May 2018 
Precision medicine for tumors
 23 May 2018 
Management of perianal fistulas in Crohn’s disease
 23 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 23 May 2018 
High body mass index is and ulcerative colitis
 22 May 2018 
Worldwide H.pylori prevalence
 22 May 2018 
PPI and risk of stroke
 22 May 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 21 May 2018 
Depressive symptoms in IBD youth
 21 May 2018 
PPI use and cognitive decline
 21 May 2018 
Fecal incontinence and quality of life in IBD
 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
Hep B in the Grey Zone
 15 May 2018 
New therapies for CDI
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohn’s
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 09 May 2018 
Esophageal dilatation in clinical practice 
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Symptom assessment in cirrhotic ascites
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Chronic Hep B
 01 May 2018 
European guidelines on pancreatic cystic neoplasms
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
Age at IBD onset and extraintestinal complications
 30 April 2018 
Formula for preterm infants
 30 April 2018 
Primary antibiotic resistance and sequential therapy for H. pylori
 27 April 2018 
Eastern and western practices for endoscopic resection of colorectal lesions
 27 April 2018 
Anxiety scale for chronic esophageal disease
 27 April 2018 
Disease activity in eosinophilic esophagitis
 26 April 2018 
Obesity and physical activity in diverticulosis
 26 April 2018 
Primary sclerosing cholangitis in the USA
 25 April 2018 
Aspirin and pancreatic cancer
 25 April 2018 
Central mediators of irinotecan-induced steatohepatitis
 25 April 2018 
Neuroimaging in Hep C
 24 April 2018 
Scoring system identifies cancer risk in Barrett's

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us